Many trials, few clear results
Research on preventing cognitive decline is abundant, and that is precisely what makes the subject hard to read. A systematic review published in 2022 recorded 112 controlled trials conducted in people without dementia, on dementia incidence or on a relevant intermediate marker.
The distribution is instructive. Thirty-three trials, or 29 percent, tested a pharmacological intervention, 27 a nutritional one, 18 physical activity, 13 cognitive stimulation, and 22 a multidomain approach. The earliest trials focused mainly on drugs or supplements, lifestyle interventions have dominated the last decade.
Of these 112 trials, only 21, or 19 percent, demonstrated a clear result. That is the number to keep in mind before promising anything. The 2024 report of the Lancet standing commission remains the reference synthesis on modifiable risk factors, but a list of associated factors is not a list of interventions that work.
The reference multidomain trial, and the real size of its effect
The Finnish FINGER trial is the most cited, and rightly so. It randomized 1,260 older people at risk between an intervention combining diet, exercise, cognitive training and vascular risk monitoring, and a control group, for two years.
The result is positive and modest. The between-group difference in the annual change of the global cognitive score was 0.022, confidence interval 0.002 to 0.042, p equal to 0.030. The interval comes close to zero at its lower bound. A later analysis showed that the benefit was observed independently of participants' baseline characteristics.
One detail rarely cited deserves to be: adverse effects occurred in 7 percent of participants in the intervention group against 1 percent in the control group, mainly musculoskeletal pain. Getting older people moving is not neutral, and it takes preparation.
Blood pressure, the best demonstrated lever
The SPRINT MIND trial compared a target of systolic pressure below 120 mmHg with a target below 140, in 9,361 people with hypertension at high cardiovascular risk, mean age 67.9.
On probable dementia, the result did not reach significance, hazard ratio 0.83 with an interval of 0.67 to 1.04, the trial having been stopped early for lack of events. But on mild cognitive impairment it was significant, hazard ratio 0.81, interval 0.69 to 0.95, as was the combined outcome, 0.85 with an interval of 0.74 to 0.97.
The extended follow-up published in 2025 confirms the same structure of results over a median of seven years: probable dementia at 0.86 with an interval that crosses 1, mild cognitive impairment at 0.87 and the combined outcome at 0.89, both significant. Controlling blood pressure protects cognition, without it yet being possible to say that it prevents established dementia.
Hearing, a real benefit that depends on the profile
The ACHIEVE trial tested hearing aids against health education in 977 people with hearing loss, mean age 76.8, over three years.
The primary result is negative. Cognitive change at three years did not differ between groups, p equal to 0.96. A pre-specified sensitivity analysis nevertheless showed a significant interaction between the two recruited sub-cohorts, p equal to 0.010: the benefit appeared in participants from an older and higher-risk cohort.
A secondary analysis published in 2025 quantified this dependence on profile. In participants in the highest predicted risk quartile, cognitive decline over three years was 61.6 percent slower with hearing aids, confidence interval 33.7 percent to 94.1 percent. In other words, the intervention does nothing on average and a great deal in those who need it most.
Physical activity, and the disagreement between two meta-analyses
It is the most universally recommended lever, and the one on which the strongest data contradict each other. A meta-analysis of 58 studies published in 2022 finds a clear association: relative risk of all-cause dementia 0.80, interval 0.77 to 0.84, across 257,983 people, 0.86 for Alzheimer's disease and 0.79 for vascular dementia. The association held even over follow-ups of twenty years or more.
A meta-analysis on individual data published in the BMJ in 2019 reaches the opposite conclusion. Covering 19 cohorts, 404,840 people with a mean age of 45.5 and 6.0 million person-years, it does find an association when activity is measured less than ten years before diagnosis, hazard ratio 1.40 for inactivity. But when the measurement precedes diagnosis by at least ten years, therefore outside the preclinical phase, the difference disappears.
The explanation put forward is reverse causation: dementia reduces physical activity in the years before it is diagnosed, which creates the association without causing it. The authors nevertheless note an excess risk in inactive people who develop cardiometabolic disease, which ties in with the blood pressure lever. Saying that moving protects the brain is therefore plausible and insufficiently proven, whereas moving protects the heart is no longer debated.
The honest position for a practitioner
The honest position fits in one sentence: the levers that protect the cardiovascular system are the ones for which cognitive evidence is least fragile, and they are also the ones with independent benefits.
Concretely, this gives an order of priority. Blood pressure first, because it is the only lever with a positive randomized trial on a cognitive outcome. Hearing next, in people already at risk, where the effect is important. Physical activity and a good diet as a permanent background, justifying them by what they do to metabolism rather than by a promise about memory.
What is not said is that a protocol prevents dementia. No trial has shown it. And memory complaints themselves deserve evaluation: an established deficit, a loss of autonomy or rapid worsening require medical referral, not a program. On the supplements presented as neuroprotective, the distance between cohorts and trials deserves a detailed look.
Sources
- 1.Livingston G, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024.
- 2.Ngandu T, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015.
- 3.Rosenberg A, et al. Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: The FINGER trial. Alzheimers Dement. 2018.
- 4.Coley N, et al. Randomised controlled trials for the prevention of cognitive decline or dementia: A systematic review. Ageing Res Rev. 2022.
- 5.Lin FR, et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial. Lancet. 2023.
- 6.Pike JR, et al. Cognitive benefits of hearing intervention vary by risk of cognitive decline: A secondary analysis of the ACHIEVE trial. Alzheimers Dement. 2025.
- 7.SPRINT MIND Investigators for the SPRINT Research Group, et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA. 2019.
- 8.Reboussin DM, et al. Long-Term Effect of Intensive vs Standard Blood Pressure Control on Mild Cognitive Impairment and Probable Dementia in SPRINT. Neurology. 2025.
- 9.Iso-Markku P, et al. Physical activity as a protective factor for dementia and Alzheimer's disease: systematic review, meta-analysis and quality assessment of cohort and case-control studies. Br J Sports Med. 2022.
- 10.Kivimäki M, et al. Physical inactivity, cardiometabolic disease, and risk of dementia: an individual-participant meta-analysis. BMJ. 2019.
Reading studies is one thing, turning them into a plan is another
The Longevity Practitioner certification teaches the method that turns this kind of data into an accompaniment decision: assess, prioritise, plan over 90 days, re-measure, and know when to hand over.
11 modules, €2,200. Enrol
Continue reading
Benjamin Sant
Co-founder of the School of Longevity
Cofounder of the School of Longevity with Tristan Maruyama. A former officer trained at Saint-Cyr from 2019 to 2022 and a coach since 2018, he has supported more than 4,000 people. He leads the School's editorial content with one constant principle: pass on only what can be situated, verified and applied seriously.
This article is published for information and education. It does not replace medical advice. For any personal health question, consult a healthcare professional.
